

# **Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H1 2018**

<https://marketpublishers.com/r/G9DBACCD5DDEN.html>

Date: April 2018

Pages: 106

Price: US\$ 3,500.00 (Single User License)

ID: G9DBACCD5DDEN

## **Abstracts**

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H1 2018

### **SUMMARY**

According to the recently published report 'Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2018'; Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) pipeline Target constitutes close to 20 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes.

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts. It stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes.

The report 'Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2018' outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and

molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 9, 3, 3, 2 and 1 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Respiratory, Musculoskeletal Disorders and Undisclosed which include indications Breast Cancer, Rheumatoid Arthritis, Hepatocellular Carcinoma, Melanoma, Solid Tumor, Colorectal Cancer, Liver Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Liver Cancer, Multiple Sclerosis, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Renal Cell Carcinoma, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Anaplastic Large Cell Lymphoma (ALCL), Ankylosing Spondylitis (Bekhterev's Disease), Basal Cell Carcinoma (Basal Cell Epithelioma), Chronic Obstructive Pulmonary Disease (COPD), Colon Carcinoma, Cutaneous T-Cell Lymphoma, Extramammary Paget Disease (EMPD), Glioblastoma Multiforme (GBM), Juvenile Myelomonocytic Leukemia (JMML), Kidney Cancer (Renal Cell Cancer), Leukemias, Lung Adenocarcinoma, Lung Cancer, Lung Disease, Lymphoma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Mycosis Fungoides, Natural Killer Cell Lymphomas, Neurotoxicity Syndromes, Nonmelanomatous Skin Cancer, Oral Cavity (Mouth) Cancer, Osteoarthritis Pain, Ovarian Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral T-Cell Lymphomas (PTCL), Prostate Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Sezary Syndrome and Unspecified.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)

The report reviews Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics and enlists all their major and minor projects

The report assesses Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Overview

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Companies Involved in

Therapeutics Development

Aduro BioTech Inc

Amgen Inc

BriaCell Therapeutics Corp

Cold Genesys Inc

Epeius Biotechnologies Corp

GlaxoSmithKline Plc

Humanigen Inc

Izana Bioscience Ltd

Mologen AG

Morphotek Inc

Sillajen Biotherapeutics

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Drug Profiles

Bria-IMT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bria-OTS - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Activate CSF2 for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Activate GMCSF for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-0070 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-0070 + Immune Checkpoint Modulator - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gimsilumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lenzilumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGN-1601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Target GMCSF for Unspecified Indication - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit GM-CSF for Immunological Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

namilumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OrienX-010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

otilimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pexastimogene devacirepvec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Reximmune-C2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBPL-0100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STINGVAX - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

talimogene laherparepvec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target CD40L and GM-CSF for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Dormant Products

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating

*Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or...*

Factor or CSF or Molgramostin or Sargramostim or CSF2) - Discontinued Products  
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating  
Factor or CSF or Molgramostin or Sargramostim or CSF2) - Product Development  
Milestones

Featured News & Press Releases

Apr 10, 2018: BriaCell to Present Encouraging Clinical Data at AACR 2018

Apr 03, 2018: BriaCell's Lead Product Candidate Mechanism of Action Described in a  
Major Immunology Journal

Mar 21, 2018: Targeted Immunotherapy Treatment Shows Promise for Treating  
Advanced Stage Liver Tumors

Mar 15, 2018: Humanigen Completes Enrollment of Phase 1 Clinical Trial of Lenzilumab  
for Treatment of Chronic Myelomonocytic Leukemia

Feb 23, 2018: SillaJen Poster Presentation at 2018 GU ASCO Symposium Highlights  
New Clinical Data in RCC, Intravenous Delivery of Pexa-Vec, Oncolytic Immunotherapy

Feb 13, 2018: Cancer-Killing Virus Acts by Alerting Immune System

Feb 06, 2018: BriaCell Opens Fourth Clinical Site in Advanced Breast Cancer

Feb 05, 2018: BriaCell Presenting at Upcoming Cancer Conference

Jan 31, 2018: BriaCell Update: Early Evidence of Efficacy and Safety of Bria-IMT

Jan 29, 2018: SillaJen Announces First Patient Enrolled in the NCI-Sponsored Trial  
Evaluating Combination Therapy in Colorectal Cancer with SillaJen's Pexa-Vec  
Oncolytic Immunotherapy

Jan 25, 2018: Humanigen CEO to Present at NobleCon14, BIO CEO Investor  
Conferences

Jan 03, 2018: BriaCell Provides Clinical Update on its Lead Immunotherapy Drug in  
Advanced Breast Cancer

Dec 14, 2017: Izana Bioscience Launches as New Clinical-Stage Translational  
Medicine Company Developing Namilumab in Ankylosing Spondylitis

Nov 06, 2017: BriaCell Provides Clinical Update on its Lead Vaccine Candidate,  
BriaVax

Oct 30, 2017: FDA Approves the Roll-Over Combination Study with Checkpoint Inhibitor  
Immunotherapies to Allow Continued Access to BriaVax in Patients with Advanced  
Breast Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us



Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018  
Number of Products under Development by Therapy Areas, H1 2018  
Number of Products under Development by Indications, H1 2018  
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018  
Number of Products under Development by Indications, H1 2018 (Contd.2), H1 2018  
Number of Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018 (Contd.1), H1 2018  
Products under Development by Companies, H1 2018 (Contd.2), H1 2018  
Products under Development by Companies, H1 2018 (Contd.3), H1 2018  
Products under Development by Companies, H1 2018 (Contd.4), H1 2018  
Number of Products under Investigation by Universities/Institutes, H1 2018  
Products under Investigation by Universities/Institutes, H1 2018  
Number of Products by Stage and Mechanism of Actions, H1 2018  
Number of Products by Stage and Route of Administration, H1 2018  
Number of Products by Stage and Molecule Type, H1 2018  
Pipeline by Aduro BioTech Inc, H1 2018  
Pipeline by Amgen Inc, H1 2018  
Pipeline by BriaCell Therapeutics Corp, H1 2018  
Pipeline by Cold Genesys Inc, H1 2018  
Pipeline by Epeius Biotechnologies Corp, H1 2018  
Pipeline by GlaxoSmithKline Plc, H1 2018  
Pipeline by Humanigen Inc, H1 2018  
Pipeline by Izana Bioscience Ltd, H1 2018  
Pipeline by Mologen AG, H1 2018  
Pipeline by Morphotek Inc, H1 2018  
Pipeline by Sillajen Biotherapeutics, H1 2018  
Dormant Products, H1 2018  
Dormant Products, H1 2018 (Contd.1), H1 2018  
Discontinued Products, H1 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018  
Number of Products under Development by Therapy Areas, H1 2018  
Number of Products under Development by Top 10 Indications, H1 2018  
Number of Products by Mechanism of Actions, H1 2018  
Number of Products by Stage and Mechanism of Actions, H1 2018  
Number of Products by Routes of Administration, H1 2018  
Number of Products by Stage and Routes of Administration, H1 2018  
Number of Products by Molecule Types, H1 2018  
Number of Products by Stage and Molecule Types, H1 2018

### COMPANIES MENTIONED

Aduro BioTech Inc  
Amgen Inc  
BriaCell Therapeutics Corp  
Cold Genesys Inc  
Epeius Biotechnologies Corp  
GlaxoSmithKline Plc  
Humanigen Inc  
Izana Bioscience Ltd  
Mologen AG  
Morphotek Inc  
Sillajen Biotherapeutics

## I would like to order

Product name: Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/G9DBACCD5DDEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G9DBACCD5DDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

